2018/02/07 Council Agenda Packet

i I t f (i)General requirements in chapter 388-877 WAC;and (ii) Program-specific requirements in WAC 388-877B-0400 through 388-877B-0450. ) (3)An agency providing opiate substitution treatment services must ensure that the agency's individual record system complies with all federal and state reporting requirements relevant to opioid I i drugs approved for use in treatment of opioid addiction. 1 (4)An agency must: I (a) Use patient placement criteria (PPC)for admission, continued services, and discharge planning i and decisions. 1 x (b) Provide education to each individual admitted,totaling no more than fifty percent of treatment i services,on: E (i)Alcohol,other drugs,and substance use disorder; ; (ii) Relapse prevention; 3 (iii) Blood borne pathogens;and i f (iv)Tuberculosis (TB). i (c) Provide education or information to each individual on: I. i x (i) Emotional, physical,and sexual abuse; i (ii) Nicotine addiction; I (iii)The impact of chemical use during risks to the fetus,and the importance of informingi pp i I medical practitioners of chemical use during pregnancy; and (iv) Family planning. ; (d) Have written procedures for: 1 (i) Diversion control that contains specific measures to reduce the possibility of the diversion of controlled substances from legitimate treatment use,and assign specific responsibility to the medical and administrative staff members for carrying out the described diversion control measures and functions. I t (ii) Urinalysis and drug testing,to include obtaining: 1 (A) Specimen samples from each individual,at least eight times within twelve consecutive months. i I (B) Random samples,without notice to the individual. 3 (C)Samples in a therapeutic manner that minimizes falsification. (D) Observed samples,when clinically appropriate. (E)Samples handled through proper chain of custody techniques. f 1 (iii) Laboratory testing. E i 3 F 4 3